CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.
Prerna Mewawalla, MD
Advertisement
Articles by Prerna Mewawalla, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer
2
Understanding “Paradigm-Changing” Events in Small Cell Lung Cancer Care
3
Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
4
Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations
5
